-5%
Linzolid is indicated for the treatment of:
- Hospital-acquired (nosocomial) pneumonia
- Community-acquired pneumonia
- Complicated skin and soft tissue infections, including diabetic foot infections (without accompanying osteomyelitis)
- Uncomplicated skin and skin structure infections
- Infections caused by Vancomycin-resistant Enterococcus faecium
Linzolid is ineffective against Gram-negative pathogens. Its safety and efficacy beyond 28 days of continuous use have not been established in clinical trials.
Linezolid is a synthetic antimicrobial agent classified as an oxazolidinone. It exhibits potent activity primarily against aerobic Gram-positive bacteria, some Gram-positive anaerobes, and selected Gram-negative species. Its mechanism involves selective inhibition of bacterial protein synthesis by binding to the 23S ribosomal RNA on the 50S ribosomal subunit. This action prevents the assembly of a functional 70S initiation complex, which is essential for bacterial translation.
Bacteriostatic: Against Enterococci and Staphylococci
Bactericidal: Against most strains of Streptococci